[A22-47] Casirivimab/imdevimab (post-exposure prophylaxis of COVID-19) – Benefit assessment according to §35a Social Code Book V
Last updated 15.07.2022
Project no.:
A22-47
Commission:
Commission awarded on 19.04.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Post-exposure prophylaxis for COVID-19 in adults and adolescents aged 12 years and older and with a body weight of at least 40 kg
Result of dossier assessment:
- Without complete immunisation, negative SARS-CoV-2 RT-qPCR test: hint of considerable added benefit
- Without complete immunisation, positive SARS-CoV-2 RT-qPCR test: hint of minor added benefit
- With complete immunisation: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-48 | Casirivimab/imdevimab (COVID-19) – Benefit assessment according to §35a Social Code Book V | Commission completed |